> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Dr. Reddy’s Recalls Mislabeled Seizure Drug
- URL: https://www.fdaweb.com/dr-reddys-recalls-mislabeled-seizure-drug/
- Published: 2025-03-14T12:00:00.000Z
- Updated: 2026-09-14T14:55:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158831

Dr. Reddy’s Laboratories is recalling (Class 1) one lot of levetiracetam in 0.75% sodium chloride injection, 1,000 mg/100 mL single-dose infusion bags because they are incorrectly labeled as levetiracetam in 0.82% sodium chloride injection 500 mg/100 mL single-dose bags. A [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-issues-nationwide-recall-levetiracetam-075-sodium-chloride-injection-1000-mg100-ml-us-due?ref=fdaweb.com) says patients who are administered the mislabeled product will likely experience adverse events, “including hypersensitivity reactions, liver injury, hematological toxicity, somnolence, fatigue, dizziness, coordination difficulties, agitation, aggression, depressed level of consciousness, respiratory depression, and coma.”

Both levetiracetam products are indicated for adjunct therapy in adults with partial onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.